272 related articles for article (PubMed ID: 16085789)
21. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
[TBL] [Abstract][Full Text] [Related]
23. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
Vigen CL; Mack WJ; Keefe RS; Sano M; Sultzer DL; Stroup TS; Dagerman KS; Hsiao JK; Lebowitz BD; Lyketsos CG; Tariot PN; Zheng L; Schneider LS
Am J Psychiatry; 2011 Aug; 168(8):831-9. PubMed ID: 21572163
[TBL] [Abstract][Full Text] [Related]
24. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
Sacchetti E; Valsecchi P; Parrinello G;
Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
[TBL] [Abstract][Full Text] [Related]
25. Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study.
Freund-Levi Y; Bloniecki V; Auestad B; Tysen Bäckström AC; Lärksäter M; Aarsland D
Dement Geriatr Cogn Disord; 2014; 38(3-4):234-44. PubMed ID: 24969380
[TBL] [Abstract][Full Text] [Related]
26. Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial.
Mowla A; Pani A
J Clin Psychopharmacol; 2010 Feb; 30(1):40-3. PubMed ID: 20075646
[TBL] [Abstract][Full Text] [Related]
27. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
Tariot PN; Schneider L; Katz IR; Mintzer JE; Street J; Copenhaver M; Williams-Hughes C
Am J Geriatr Psychiatry; 2006 Sep; 14(9):767-76. PubMed ID: 16905684
[TBL] [Abstract][Full Text] [Related]
28. The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.
Madhusoodanan S; Bogunovic O
CNS Spectr; 2007 Jan; 12(1):46-50. PubMed ID: 17192763
[TBL] [Abstract][Full Text] [Related]
29. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
Robinson DG; Woerner MG; Napolitano B; Patel RC; Sevy SM; Gunduz-Bruce H; Soto-Perello JM; Mendelowitz A; Khadivi A; Miller R; McCormack J; Lorell BS; Lesser ML; Schooler NR; Kane JM
Am J Psychiatry; 2006 Dec; 163(12):2096-102. PubMed ID: 17151160
[TBL] [Abstract][Full Text] [Related]
30. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
Sachs GS; Grossman F; Ghaemi SN; Okamoto A; Bowden CL
Am J Psychiatry; 2002 Jul; 159(7):1146-54. PubMed ID: 12091192
[TBL] [Abstract][Full Text] [Related]
31. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.
Alvarez E; Ciudad A; Olivares JM; Bousoño M; Gómez JC
J Clin Psychopharmacol; 2006 Jun; 26(3):238-49. PubMed ID: 16702888
[TBL] [Abstract][Full Text] [Related]
32. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
[TBL] [Abstract][Full Text] [Related]
33. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
Street JS; Clark WS; Gannon KS; Cummings JL; Bymaster FP; Tamura RN; Mitan SJ; Kadam DL; Sanger TM; Feldman PD; Tollefson GD; Breier A
Arch Gen Psychiatry; 2000 Oct; 57(10):968-76. PubMed ID: 11015815
[TBL] [Abstract][Full Text] [Related]
34. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
35. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances.
Suh GH; Son HG; Ju YS; Jcho KH; Yeon BK; Shin YM; Kee BS; Choi SK
Am J Geriatr Psychiatry; 2004; 12(5):509-16. PubMed ID: 15353389
[TBL] [Abstract][Full Text] [Related]
36. A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.
Katagiri H; Fujikoshi S; Suzuki T; Fujita K; Sugiyama N; Takahashi M; Gomez JC
BMC Psychiatry; 2013 Jan; 13():20. PubMed ID: 23311957
[TBL] [Abstract][Full Text] [Related]
37. The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients.
Kinon BJ; Stauffer VL; McGuire HC; Kaiser CJ; Dickson RA; Kennedy JS
J Am Med Dir Assoc; 2003; 4(4):189-94. PubMed ID: 12837139
[TBL] [Abstract][Full Text] [Related]
38. Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice.
Kurz A; Schwalen S S; Schmitt A
Int Psychogeriatr; 2005 Dec; 17(4):605-16. PubMed ID: 16185378
[TBL] [Abstract][Full Text] [Related]
39. Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects.
Lane HY; Chang YC; Su MH; Chiu CC; Huang MC; Chang WH
J Clin Psychopharmacol; 2002 Feb; 22(1):4-10. PubMed ID: 11799336
[TBL] [Abstract][Full Text] [Related]
40. Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Devanand DP; Mintzer J; Schultz SK; Andrews HF; Sultzer DL; de la Pena D; Gupta S; Colon S; Schimming C; Pelton GH; Levin B
N Engl J Med; 2012 Oct; 367(16):1497-507. PubMed ID: 23075176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
